Second‐line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild‐type KRAS

The goal of the present study was to compare the efficacy of the combination of cetuximab and irinotecan to the combination of oxaliplatin and fluoropyrimidines as second‐line chemotherapy in patients with irinotecan‐refractory and oxaliplatin‐naïve metastatic colorectal cancer (mCRC) harboring wild...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Sci
Auteurs principaux: Hong, Yong Sang, Kim, Hwa Jung, Park, Seong Joon, Kim, Kyu‐Pyo, Lee, Jae‐Lyun, Park, Jin Hong, Kim, Jong Hoon, Lim, Seok‐Byung, Yu, Chang Sik, Kim, Jin Cheon, Baek, Ji Yeon, Kim, Sun Young, Kim, Tae Won
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2013
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657158/
https://ncbi.nlm.nih.gov/pubmed/23298313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12098
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires